Navigation Links
ERT Reports Second Quarter 2011 Operating Results on August 1, 2011
Date:7/22/2011

PHILADELPHIA, July 22, 2011 /PRNewswire/ -- ERT (NASDAQ: ERT) announced today that it will release its operating results for the second quarter 2011 Monday, August 1, after the market closes.  After the release, the Company will host a conference call at 5:00 PM ET that day.

For the conference call, interested participants should dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when calling internationally. There will be a playback available as well. To listen to the playback, please call 1-877-344-7529 when calling within the United States or 1-412-317-0088 when calling internationally.  Conference code for playback is 10002497.

This call is being webcast by MultiVu and can be accessed at ERT's website at www.ert.com. The webcast may also be accessed via the direct link at http://www.videonewswire.com/event.asp?id=81200.   The webcast can be accessed for up to one year on either site.  

ERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.  It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Media Contact:

Keith Schneck, CFO
Tel: 215-972-0420
kschneck@ert.com


'/>"/>
SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Champions Oncology Reports Full Year 2011 Financial Results
2. ReportsnReports - Daptomycin - Comprehensive Patent Search
3. UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits
4. OncoSec Medical Reports Third Quarter 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
7. Soligenix Reports First Quarter 2011 Financial Results and Reviews Accomplishments
8. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
9. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
10. PharmAthene Reports First Quarter 2011 Financial and Operating Results
11. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017  Perthera,s Chief Bioinformatics Officer and research ... Madhavan , Ph.D., will be speaking at the American ... Monday, March 27, 2017, she will be speaking on ... for Research and Care" (from 10:30 a.m. – 12:00 ... will be a participant in the "Making Precision Oncology ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased ... conference presented by The Conference Forum in Boston on April 3-4, 2017. The CTC ... improved clinical trial outcomes and bring them closer to the patient. Clinical Trial Collaborations ...
(Date:3/27/2017)... SAN DIEGO , March 27, 2017  Trovagene, ... announced that its Chief Executive Officer, Bill Welch ... on April 4, 2017 at 9:00 AM EDT at ... .  Bill Welch, and Chief Scientific Officer, ... meet with investors during the conference.   The ...
(Date:3/27/2017)... March 27, 2017 Neurotrope, Inc. (OTCQB: ... for neurodegenerative diseases, including Alzheimer,s disease, today announced ... to list the Company,s common stock on the ... NASDAQ Stock Market, a unit of the NASDAQ ... ring the Opening Bell at the NASDAQ MarketSite ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
Breaking Biology News(10 mins):